Business Details
Targeted Nanosphere Therapies for Oncology Innovation
At NanoValent Pharmaceuticals, we are pioneering a revolutionary approach to targeted cancer therapies through our proprietary Targeted Nanosphere (TNS) platform. Our technology leverages hybrid polymerized liposomal nanoparticles (HPLN) to significantly enhance the efficacy, safety, and delivery of both existing and emerging therapeutic agents, including chemotherapeutics, biologics, and nucleic acid-based treatments. Founded in collaboration with Childrens Hospital Los Angeles and leading US academic institutions, our team has developed a robust pipeline of candidates, with NV103 (Irinotecan-anti-CD99) nearing Investigational New Drug (IND) status and poised for clinical trials in 2026.Our executive leadership brings decades of experience in pharmaceutical innovation, clinical research, and operational excellence, ensuring rigorous scientific standards and strategic execution. Backed by NIH, NCI, and NSF grants, along with private investments, we are advancing our platform to address unmet needs in oncology and beyond, including neurology applications enabled by our ability to cross the blood-brain barrier. With a proven track record of success and a strong intellectual property portfolio, we are committed to transforming therapeutic outcomes for patients worldwide.
Services
Drug Development
Oncology Therapeutics
Nanoparticle Engineering
Targeted Delivery Systems
Clinical Research
Highlights and features
- Our founders hold groundbreaking patents in nanoparticle chemistry from top institutions
- NV103 demonstrated 40x tumor-killing efficacy versus standard treatments in pre-clinical models
- Experienced leadership team with successful exits in oncology pharmaceuticals
- Proven ability to cross blood-brain barriers for neuro-oncology applications
- Strategic partnerships with Children's Hospital Los Angeles and Boston University
Services
NV103 Development
NV103 combines Irinotecan with anti-CD99 targeting for glioblastoma, pancreatic, ovarian, and Ewing sarcoma treatment. This candidate demonstrates significantly enhanced efficacy through precise tumor cell targeting while minimizing systemic toxicity. Currently approaching IND status with planned clinical validation in 2026.
HPLN Platform
Our Hybrid Polymerized Liposomal Nanoparticle technology enables programmable drug delivery systems. This platform supports diverse payloads including chemotherapeutics, biologics, and nucleic acids while maintaining antibody-mediated targeting precision. Underlying IP protects broad pharmaceutical applications.
NV102 Research
NV102 delivers doxorubicin via anti-CD19 targeting for acute leukemias. Demonstrated 10-12x greater efficacy than standard liposomal formulations in pre-clinical testing. Part of our multi-pronged oncology pipeline leveraging TNS technology.
People
Jon Nagy
Chief Scientific Officer and President
PhD in synthetic organic chemistry from Iowa State University with 40+ years nanotechnology R&D experience including Lawrence Berkeley National Laboratory and LigoCyte Pharmaceuticals. Led key nanoparticle patent development.
Timothy Triche
Chief Medical Officer
Board-certified pathologist and pediatric oncology expert at Children's Hospital Los Angeles. Tenured USC faculty member with executive leadership in multiple biotech startups. Focus on tumor cell biology.
Mark Lewis
Chief Executive Officer
International pharma executive with leadership roles at Amersham, Chiron, and SuperGen. Holds biochemistry honors degree with business qualifications. Specializes in oncology market development and clinical operations.
Questions
What distinguishes NanoValent's TNS technology from conventional ADCs?
Our TNS platform allows programmable payload combinations and superior tumor targeting with demonstrated 40x efficacy improvements over standard therapies.
Which cancers are currently targeted by your pipeline candidates?
NV103 focuses on CD99-expressing tumors (glioblastoma, pancreatic, ovarian, Ewing sarcoma) while NV102 targets hematologic malignancies like AML and ALL.
How does your technology cross the blood-brain barrier?
HPLN nanoparticles leverage size optimization and surface chemistry to effectively penetrate neurological barriers, enabling treatment of brain tumors and neurodegenerative diseases.
What collaborations support your research programs?
We collaborate with Children's Hospital Los Angeles for clinical validation and Boston University for diagnostic microsphere development through STTR funding.
